文献速递淋巴瘤

淋巴结B细胞淋巴瘤自体培养模型揭示双特异性抗体体外应答决定因素

An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies.
PubMed 文献 · Blood Adv · 2021-01-01

研究建立原代自体培养模型,在淋巴结微环境中模拟CD3xCD19与CD3xCD20双特异性抗体治疗。体外应答与T细胞扩增和效应分子分泌相关,特定调节性T细胞表型与应答独立相关,来那度胺、纳武利尤单抗和阿替利珠单抗可改善体外应答。

要点

  • 体外应答与T细胞扩增及颗粒酶B、穿孔素分泌相关,与耗竭/活化标志物无关。
  • Aiolos、ICOS、CXCR5高表达与良好体外应答相关,Helios强表达不利。
  • 来那度胺、纳武利尤单抗和阿替利珠单抗可增强T细胞效应功能改善体外应答。

核心结论

  • 独特的调节性T细胞表型可能是双特异性抗体治疗失败的潜在因素。
  • 来那度胺、纳武利尤单抗和阿替利珠单抗等药物组合可能提高双特异性抗体疗效。

研究设计与样本

  • 建立原代自体培养模型,在体外淋巴结微环境中模拟CD3xCD19和CD3xCD20双特异性抗体治疗。

主要发现

  • T细胞介导的淋巴瘤细胞杀伤和T细胞增殖在患者间差异显著,但靶向CD20或CD19的双特异性抗体之间高度相关。
  • 体外应答与T细胞扩增和效应分子(如颗粒酶B、穿孔素)分泌显著相关,与T细胞耗竭标志物(如PD1、TIM3)、活化标志物(如CD25、CD69)或细胞间接触形成无关。
  • 鉴定出与体外应答相关的独特调节性T细胞表型,且独立于基线T细胞频率。
  • Aiolos(IKZF1)、ICOS和CXCR5高表达与体外应答正相关,Helios(IKZF2)强表达对体外应答有不利影响。
  • 来那度胺、纳武利尤单抗和阿替利珠单抗通过增强T细胞效应功能改善体外对双特异性抗体的应答。

临床怎么用

  • 可通过检测调节性T细胞表型(Aiolos、ICOS、CXCR5、Helios)辅助预测双特异性抗体疗效。
  • 来那度胺、纳武利尤单抗和阿替利珠单抗或可与双特异性抗体联合使用以提高疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific antibodies (BsAbs) can induce long-term responses in patients with refractory and relapsed B-cell lymphoma. Nevertheless, response rates across patients are heterogeneous, and the factors determining quality and duration of responses are poorly understood. To identify key determinants of response to BsAbs, we established a primary, autologous culture model allowing us to mimic treatment with CD3xCD19 and CD3xCD20 BsAbs within the lymph node microenvironment ex vivo. T cell-mediated killing of lymphoma cells and proliferation of T cells varied significantly among patients but highly correlated between BsAbs targeting CD20 or CD19. Ex vivo response to BsAbs was significantly associated with expansion of T cells and secretion of effector molecules (eg, granzyme B, perforin) but not with expression of T-cell exhaustion (eg, PD1, TIM3) or activation markers (eg, CD25, CD69) or formation of intercellular contacts. In addition, we identified a distinct phenotype of regulatory T cells that was linked to ex vivo response independently from T-cell frequency at baseline. High expression levels of Aiolos (IKZF1), ICOS, and CXCR5 were positively associated with ex vivo response, whereas strong expression of Helios (IKZF2) had an unfavorable impact on ex vivo response to BsAbs. We further showed that lenalidomide, nivolumab, and atezolizumab improved ex vivo response to BsAbs by potentiating T-cell effector functions. In summary, our ex vivo study identified a distinct regulatory T-cell phenotype as a potential contributor to treatment failure of BsAbs and suggests drug combinations of high clinical relevance that could improve the efficacy of BsAbs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Roider T, Brinkmann BJ, Kim V, et al. An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. Blood Adv. 2021. PMID: 34587238. doi:10.1182/bloodadvances.2021005400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。